Signals via API

Public sample from today's flagship detail endpoint. Public payloads can be limited or redacted. The backend exposes read endpoints for signals, storylines, and briefings.

GET /v1/narratives/82d9c4f7-c631-42c9-aac7-146403d034bf?tenant=biotech

{
  "id": "82d9c4f7-c631-42c9-aac7-146403d034bf",
  "title": "Head-to-head trial dents Novo Nordisk's obesity hopes",
  "summary": "Head-to-head trial dents Novo Nordisk's obesity hopes Phil.Taylor Mon, 23/02/2026 - 12:04",
  "first_seen_at": "2026-02-23T12:04:44Z",
  "last_seen_at": "2026-02-23T17:22:33Z",
  "created_at": "2026-02-23T18:04:32.768239Z",
  "updated_at": "2026-02-24T06:05:53.482071Z",
  "timeframe": "24h",
  "run_id": null,
  "metrics": {
    "divergence": 29.6666,
    "post_count": 5,
    "momentum_1h": 0,
    "momentum_7d": 5,
    "score_total": 1.775185,
    "shill_score": 6,
    "momentum_24h": 5,
    "market_movers": [],
    "evidence_score": 1,
    "unique_authors": 5,
    "coherence_score": 0.7396,
    "diversity_bonus": 0.25,
    "duplicate_ratio": 0.2,
    "platforms_count": 2,
    "social_momentum": 5,
    "divergence_label": "chatter_without_pricing",
    "market_conviction": 0,
    "origin_share_top1": 0.4,
    "unique_publishers": 5,
    "origin_layer_posts": 0,
    "source_types_count": 2,
    "unique_authors_24h": 5,
    "unique_origin_urls": 5,
    "amplifier_share_top1": 0.2,
    "author_concentration": 0.2,
    "publisher_share_top1": 0.2,
    "amplifier_layer_posts": 5,
    "concentration_penalty": 0,
    "unique_origin_domains": 4,
    "source_diversity_bonus": 0.2,
    "unique_publisher_types": 2,
    "unique_origin_publishers": 4
  },
  "platforms": [
    "rss",
    "x"
  ],
  "top_tickers": [],
  "why_now": [],
  "display_title": "Novo’s Next-Gen Obesity Shot Fails to Match Lilly Drug in Head-to-Head Study",
  "display_summary": "Novo Nordisk's CagriSema has failed to outperform Eli Lilly's Zepbound in a critical phase 3 weight loss study, resulting in a significant drop in the company's stock price.",
  "narrative_frame_display": "Novo Nordisk's latest obesity treatment, CagriSema, has faced significant setbacks in clinical trials, failing to outperform Eli Lilly's Zepbound in a head-to-head study. This disappointing outcome has led to a sharp decline in Novo Nordisk's stock price, reflecting investor concerns about the future of its obesity drug portfolio.",
  "display_tags": [
    "equities",
    "fiercebiotech_biopharma_dive"
  ],
  "tags": [
    "equities",
    "fiercebiotech_biopharma_dive"
  ],
  "cscope_tags": [
    "equities",
    "fiercebiotech_biopharma_dive"
  ],
  "why_now_display": [
    "The results from the phase 3 trial were released recently, prompting immediate market reactions.",
    "Investors are closely monitoring the implications for Novo Nordisk's overall strategy in the obesity market.",
    "The competitive landscape in obesity treatments is rapidly evolving, making these results critical."
  ],
  "why_it_matters_display": [
    "CagriSema's failure raises questions about Novo Nordisk's competitive edge in obesity treatments.",
    "The stock drop reflects investor concerns over the viability of Novo's obesity drug pipeline.",
    "This setback could impact future funding and development for Novo Nordisk's obesity initiatives."
  ],
  "show_why": true,
  "sources_display": [
    {
      "url": "https://www.fiercebiotech.com/biotech/novos-cagrisema-loses-phase-3-battle-mounjaro-knocking-15-share-price",
      "label": "fiercebiotech.com: FierceBiotech",
      "published_at": "2026-02-23T14:15:23+00:00"
    },
    {
      "url": "https://www.biopharmadive.com/news/novo-nordisk-cagrisema-zepbound-head-to-head-results/812810/",
      "label": "biopharmadive.com: BioPharma Dive",
      "published_at": "2026-02-23T17:22:33+00:00"
    },
    {
      "url": "https://www.theguardian.com/business/2026/feb/23/wegovy-ozempic-weight-loss-drug-novo-nordisk-cagrisema",
      "label": "theguardian.com: guardian_science",
      "published_at": "2026-02-23T14:26:30+00:00"
    },
    {
      "url": "https://pharmaphorum.com/news/head-head-trial-dents-novo-nordisks-obesity-hopes",
      "label": "pharmaphorum: Head-to-head trial dents Novo Nordisk's obesity hopes",
      "published_at": "2026-02-23T12:04:44+00:00"
    }
  ],
  "llm_status": "ok",
  "llm_meta": {
    "model": "gpt-4o-mini",
    "prompt_version": "enrich_v2",
    "input_hash": "ca24ceb2d0422b87203ce748510fd211f61d71a0889605074e3771b7b455ebad",
    "updated_at": "2026-02-24T06:08:02.671503+00:00",
    "llm_metadata": {
      "env": "prod",
      "host": "e47ed83e0442",
      "stage": "signals.enrich",
      "run_id": "80e0ae1c-00d5-4e87-aa9d-6b8032d5e4b2",
      "tenant": "biotech",
      "service": "api",
      "pipeline": "pipeline_run",
      "correlation_id": "82d9c4f7-c631-42c9-aac7-146403d034bf"
    }
  },
  "story_id": "3690eb5d-406f-43ee-845a-9dc4dae36f3c"
}

• Signals and storylines feed endpoints with filtering and rate limits
• Briefing delivery endpoints for integrations
• Evidence link payloads for auditability

• Route top stories into Slack or Teams for morning and evening desk updates.
• Sync storyline evidence into Notion, Airtable, or internal research trackers.
• Feed metrics into BI dashboards for momentum, concentration, and source mix monitoring.

Quick start endpoints: /v1/feed/stories, /v1/signals, /v1/storylines/search, /v1/briefings/latest.

For product access, see Pricing.